Company Profile

Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Industry Classifications

Sector

Healthcare

Industry

Biotechnology

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (541710)

SIC

Commercial Physical and Biological Research (8731)

Contact Information

Investor Relations

Sutro Biopharma
Emily White
Executive Director, Investor Relations and Communications
T: 650-823-7681
ewhite@sutrobio.com

Company Contact

Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080